Target ALS and AFTD have announced $5 million in grants for research by six different teams to aid in the discovery of biomarkers and viable treatments for ALS and FTD, which overlap in genetic causes and biological mechanisms. Several of the teams who were awarded these grants include former AFTD grant recipients.

By joining forces, Target ALS and AFTD are leveraging the combined expertise of researchers in two fields, fueling collaboration in support of the most promising ideas. These newly funded projects will inform, and potentially result in, both viable treatments and the biomarkers critically needed to enable accurate diagnosis and measure disease progression.

“We’re proud to join Target ALS in announcing funding for these crucial funding efforts,” AFTD CEO Susan L-J Dickinson, MSGC, said. “With the challenges that the COVID-19 pandemic is adding for the families we serve, we want them to know that we are working as hard as ever to bring momentum for a day when treatments can halt FTD and ALS in their tracks.”

Click here for more information on the research partnership, including a brief overview of each funded award.